# Edding Pharm

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/edding-pharm

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.eddingpharm.com
- Total disclosed funding: $127M
- Latest round: Series C (Nov 27, 2019)
- Investors on record: 9

## About

Established in 2001 and based in Shanghai, China, Edding Pharm operates as a new drug developer focusing to the development of new antitumor drugs. It cooperates with GSK and Amarin. In November 2019, the company raised USD 71 million in series C funding. In October 2024, it merged with Genor Biopharma Co. Ltd., a portfolio company of Qiming Venture Partners, Haitong Capital, and other investors to form Edding Genor Group Holdings Limited.

The company mainly develops new drugs for three disease areas, which are anti-infection, cardiovascular, and respiratory system. In the field of anti-infection, it has anti-infective drugs Vancocin® and Ceclor®. The Vancocin® is a drug for treating MRSA (Meticillin Resistant Staphylococcus aureus) infection. The Ceclor® is a pediatric antibacterial drug used to treat respiratory infections in pediatric patients. In the field of cardiovascular, the company has Vascepa®, which can be used to reduce cardiovascular risks in targeted high-risk patients. Edding Pharm also provides new antitumor drugs. 

The company generates revenue by providing new drugs for disease areas such as anti-infection, cardiovascular, respiratory system, and oncology.

## Funding rounds

- Series C, Nov 27, 2019, $71M — Hong Shan, YuanBio Venture, Everest VC, Yingke Private Equity, TF Capital, Hanne Capital
- Series B, Nov 7, 2017, $32M — Hong Shan, H&Q Asia Pacific, Taikang Asset Management
- Series B, Jul 30, 2010, $24M — OrbiMed Advisors, Hong Shan, H&Q Asia Pacific

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Hong Shan — Series B, Series C
- H&Q Asia Pacific (https://capitalatlas.ai/funds/h-q-asia-pacific) — Series B
- Taikang Asset Management — Series B
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series C
- Everest VC (https://capitalatlas.ai/funds/everest-vc) — Series C
- Yingke Private Equity (https://capitalatlas.ai/funds/yingke-private-equity) — Series C
- TF Capital — Series C
- Hanne Capital (https://capitalatlas.ai/funds/hanne-capital) — Series C